Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418783 | 0.91 | KMT2A (0.42) | LMNASMN1; SMN2KMT2AHTTTSHR | |
| SCHEMBL4421900 | 0.88 | LMNA (0.40) | LMNASMN1; SMN2KMT2AHTTTSHR | |
| SCHEMBL4424440 | 0.86 | HSD11B1 (0.41) | LMNASMN1; SMN2KMT2AKDM1AKDM4E | |
| SCHEMBL4421354 | 0.85 | SLC6A9 (0.43) | LMNASMN1; SMN2KMT2AHTTKDM4E | |
| SCHEMBL4415378 | 0.81 | HTT (0.45) | LMNASMN1; SMN2KMT2AHTTTSHR | |
| SCHEMBL4415375 | 0.80 | HTT (0.53) | LMNASMN1; SMN2KMT2AHTTMAPK1 | |
| SCHEMBL4420883 | 0.76 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1SLC6A9GAA | |
| SCHEMBL4430192 | 0.74 | MCOLN3 (0.44) | LMNASMN1; SMN2KMT2AHTTTSHR | |
| SCHEMBL2170672 | 0.73 | KMT2A (0.41) | LMNASMN1; SMN2KMT2AHTTTSHR | |
| SCHEMBL4424423 | 0.73 | ALDH1A1 (0.40) | LMNASMN1; SMN2KDM1AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473787-B2 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | LMNA 4565/4885SMN1; SMN2 4003/4885KMT2A 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.